The Frederick National Laboratory and the University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR) will work under a formal collaboration to evaluate the effectiveness of new compounds that might be used to enhance the immune response to vaccines.
Vaccine adjuvants are compounds used as additives to some vaccines. Adjuvants enhance the immune response elicited by a vaccine, thereby making the vaccine more effective.
IBBR has novel formulations of adjuvants (polyphosphazene immunoadjuvants) that will be evaluated under the collaboration.
Jason Marshall, Ph.D., of the Frederick National Laboratory will work with IBBR Research Fellow Alexander Andrianov, Ph.D., to evaluate IBBR’s polyphosphazenes, biodegradable synthetic macromolecules that have demonstrated the ability to stimulate the immune system.
These macromolecules are also efficient in prolonging the shelf-life of vaccines and capable of reducing the dose of the antigenic protein needed for protective immune response, Andrianov said.
“External collaborations such as the one with the Institute for Bioscience and Biotechnology Research may extend the repertoire of novel adjuvants we can utilize to optimize novel cancer vaccine technologies in the preclinical setting,” added Marshall.